Throat infection, neck and chest pain and cardiac response: A persistent infection-related clinical syndrome

  • Changqing Zhou (周昌清)
  • Xiangning Fu (付向宁)
  • Jiangtao Yan (严江涛)
  • Qiao Fan (范 巧)
  • Zhuoya Li (李卓娅)
  • Katherine Cianflone
  • Daowen Wang (汪道文)


Dizziness, chest discomfort, chest depression and dyspnea are a group of symptoms that are common complaints in clinical practice. Patients with these symptoms are usually informed that while neurosis consequent to coronary heart disease is excluded nonetheless they remain unhealthy with no rational explanation or treatment. 165 cases of these symptoms and 85 control subjects were reviewed and underwent further medical history inquiry, routine EKG test and cardiac ultrasound examination. Thirty-five patients received coronary artery angiography to exclude coronary heart disease. Serum myocardial autoantibodies against beta1-adrenoceptor, alpha-myosin heavy chain, M2-muscarinic receptor and adenine-nucleotide translocator were tested, and inflammatory cytokines and high sensitivity C-reaction protein were measured and lymphocyte subclass was assayed by flow cytometry. All patients had a complex of four symptoms or tetralogy: (1) persistent throat or upper respiratory tract infection, (2) neck pain, (3) chest pain and (4) chest depression or dyspnea, some of them with anxiety. Anti-myocardial autoantibodies (AMCAs) were present in all patients vs. 8% in controls. TNF-α, IL-1 and IL-6 were significantly higher in patients than in controls (P<0.01). CD3+ and CD4-CD8+ lymphocytes were significantly higher and CD56+ lymphocytes lower in patients than those in controls (P<0.01). The ratio of serum pathogen antibodies positive against Coxsackie virus-B, cytomegalovirus, Mycoplasma pneumoniae and Chlamydia pneumoniae were all markedly higher in patients. These data led to identification of a persistent respiratory infection-related clinical syndrome, including persistent throat infection, neck spinal lesion, rib cartilage inflammation, symptoms of cardiac depression and dyspnea with or without anxiety.

Key words

inflammation chest pain cardiac response diagnosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kontos MC, Jesse RL. Evaluation of the emergency department chest pain patient. Am J Cardiol, 2000,85(5, Supplement 1):32–39CrossRefGoogle Scholar
  2. 2.
    Marsan RJ Jr, Shaver KJ, Sease KL, et al. Evaluation of a clinical decision rule for young adult patients with chest pain. Acad Emerg Med, 2005,12(1):26–31PubMedCrossRefGoogle Scholar
  3. 3.
    Watson GS. Noncardiac chest pain: a rational approach to a common complaint. JAAPA, 2006,19(1):20–25PubMedGoogle Scholar
  4. 4.
    Olden KW. Treatment of noncardiac chest pain of psychological origin. Curr Treat Options Gastroenterol, 2006, 9:51–58PubMedCrossRefGoogle Scholar
  5. 5.
    Staudt A, Mobini R, Fu M, et al. beta(1)-Adrenoceptor antibodies induce positive inotropic response in isolated cardiomyocytes. Eur J Pharmacol, 2001,423:115–119PubMedCrossRefGoogle Scholar
  6. 6.
    Caforio AL, Goldman JH, Haven AJ, et al. Evidence for autoimmunity to myosin and other heart-specific autoantigens in patients with dilated cardiomyopathy and their relatives. Int J Cardiol, 1996,54:157–163PubMedCrossRefGoogle Scholar
  7. 7.
    Schwimmbeck PL, Bland NK, Schultheiss HP, et al. The possible value of synthetic peptides in the diagnosis and therapy of myocarditis and dilated cardiomyopathy. Eur Heart J, 1991, 12Suppl D:76–80PubMedGoogle Scholar
  8. 8.
    Fu LX, Magnusson Y, Bergh CH, et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest, 1993,91:1964–1968PubMedCrossRefGoogle Scholar
  9. 9.
    Schwimmbeck PL, Schwimmbeck NK, Schultheiss HP, et al. Mapping of antigenic determinants of the adenine- nucleotide translocator and coxsackie B3 virus with synthetic peptides: use for the diagnosis of viral heart disease. Clin Immunol Immunopathol, 1993,68:135–140PubMedCrossRefGoogle Scholar
  10. 10.
    Baba A, Yoshikawa T, Chino M, et al. Characterization of anti-myocardial autoantibodies in Japanese patients with dilated cardiomyopathy. Jpn Circ J, 2001,65:867–873PubMedCrossRefGoogle Scholar
  11. 11.
    Agard A, Bentley L, Herlitz J. Experiences and concerns among patients being treated for atypical chest pain. Eur J Intern Med, 2005,16:339–344PubMedCrossRefGoogle Scholar
  12. 12.
    Esler JL, Bock BC. Psychological treatments for noncardiac chest pain: recommendations for a new approach. J Psychosom Res, 2004,56:263–269PubMedCrossRefGoogle Scholar
  13. 13.
    Eriksson U, Penninger JM, Kopf M. Mechanisms of autoimmune heart disease. Drug Discovery Today: Disease Mechanisms, 2004,1(3):283–288CrossRefGoogle Scholar
  14. 14.
    Yndestad A, Holm AM, Muller F, et al. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res, 2003,60:141–146PubMedCrossRefGoogle Scholar
  15. 15.
    Basinkevich AB, Shakhnovich RM, Martynova VR, et al. [Role of Chlamydia, mycoplasma and cytomegalovirus infection in the development of coronary artery disease]. Kardiologiia, 2003,43:4–9PubMedGoogle Scholar
  16. 16.
    Smieja M, Gnarpe J, Lonn E, et al. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation, 2003,107:251–257PubMedCrossRefGoogle Scholar
  17. 17.
    Reunanen A, Roivainen M, Kleemola M. Increased titer of antibodies to Mycoplasma pneumoniae may be associated with coronary heart disease. Atherosclerosis, 2005,180:209–210PubMedCrossRefGoogle Scholar
  18. 18.
    Fu ML, Hoebeke J, Matsui S, et al. Autoantibodies against Cardiac G-Protein-Coupled Receptors Define Different Populations with Cardiomyopathies but Not with Hypertension, Clin Immunol Immunopathol. 1994,72(1):15–20PubMedCrossRefGoogle Scholar
  19. 19.
    Matsui S, Fu ML, Katsuda S, et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol, 1997,29:641–655PubMedCrossRefGoogle Scholar
  20. 20.
    Matsui S, Fu ML, Hayase M, et al. Active immunization of combined [beta]1-adrenoceptor and M2-muscarinic receptor peptides induces cardiac hypertrophy in rabbits, J Card Fail. 1999, 5(3):246–254PubMedCrossRefGoogle Scholar
  21. 21.
    Jahns R, Boivin V, Krapf T, et al. Modulation of beta1-adrenoceptor activity by domain-specific antibodies and heart failure-associated autoantibodies. J Am Coll Cardiol, 2000,36:1280–1287PubMedCrossRefGoogle Scholar
  22. 22.
    Jahns R, Boivin V, Lohse MJ. beta(1)-Adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy. Trends Cardiovasc Med, 2006,16:20–24PubMedCrossRefGoogle Scholar
  23. 23.
    Manchado C, Orus J, Villarroya F, et al. Epitope mapping of mitochondrial adenine nucleotide translocase-1 in idiopathic dilated cardiomyopathy. J Mol Cell Cardiol, 2002,34:571–582PubMedCrossRefGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag GmbH 2009

Authors and Affiliations

  • Changqing Zhou (周昌清)
    • 1
    • 2
  • Xiangning Fu (付向宁)
    • 1
  • Jiangtao Yan (严江涛)
    • 1
  • Qiao Fan (范 巧)
    • 1
  • Zhuoya Li (李卓娅)
    • 3
  • Katherine Cianflone
    • 4
  • Daowen Wang (汪道文)
    • 1
  1. 1.The Institute of Hypertension and Cardiovascular Division, Department of Internal Medicine, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of CardiologyHefei First People’s HospitalHefeiChina
  3. 3.Department of Immunology, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  4. 4.Centre de Recherche Hopital LavalUniversite LavalSte FoyCanada

Personalised recommendations